Business
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing
About this update from Rezolute, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. “We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for potential commercialization,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “Erik brings a unique blend of strategic vision, operational excellence, and dedication to serving the needs of patients and their families.” Mr. Harris is an experienced board member and commercial leader with a proven track record in the industry. Mr. Harris has spearheaded global product launches, built and led high-performing commercial teams, and fostered strategic partnerships while navigating complex markets and achieving ambitious growth targets. “I'm excited to join the Rezolute board at such a pivotal time,” said Mr. Harris. “I'm very impressed with the company's evolution and believe that ersodetug has already demonstrated the ability to significantly improve the quality of life for individuals with hyperinsulinism. I look forward to helping guide the company in the next phase of its development.” About Rezolute, Inc.Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com. Forward-Looking StatementsThis release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities ...